de Bruin, I. J. A. http://orcid.org/0000-0002-5776-4971
Klop, C.
Wyers, C. E.
Overbeek, J. A.
Geusens, P. P. M. M.
van den Bergh, J. P. W.
Driessen, J. H. M.
de Vries, F.
Funding for this research was provided by:
ZonMw (113101007)
Article History
Received: 7 September 2018
Accepted: 10 January 2019
First Online: 8 February 2019
Compliance with ethical standards
:
: Dr. de Bruin reports personal fees from Pfizer, personal fees from Novartis, personal fees from Sanofi, outside the submitted work;Dr. Klop has nothing to disclose;Dr. Wyers has nothing to disclose;Dr. Overbeek reports other from Universiteit Utrecht / Universitair Medisch Centrum Maastricht, during the conduct of the study; Comment: Employee of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies. The PHARMO Institute received funding from Universiteit Utrecht / Universitair Medisch Centrum Maastricht for this study.Dr. Geusens reports grants and personal fees from Amgen, grants from Pfizer, grants from MSD, grants from UCB, grants from Abbott, grants and personal fees from Lilly, grants from BMS, grants from Novartis, grants from Roche, grants from Will Pharma, outside the submitted work.Dr. van den Bergh reports grants and personal fees from Amgen, grants and personal fees from Eli Lilly, personal fees from UCB, outside the submitted work; .Dr. Driessen has nothing to disclose;Dr. de Vries reports that he supervises a PhD student who is also employed with F. Hoffmann la Roche ltd., Basel, Switzerland. The topic of this PhD is not related to the current manuscript. I have not received any reimbursments or fees for this.